A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH NEOADJUVANT DOXORUBICIN + CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL + TRASTUZUMAB + PERTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER
Brief description of study
The purpose of this study is to compare the effects, good or bad, of atezolizumab in combination with chemotherapy, trastuzumab, and pertuzumab versus placebo in combination with chemotherapy, trastuzumab, and pertuzumab on you and your HER2 positive breast cancer to find out which is better. The chemotherapy drugs used in this study are known as doxorubicin, cyclophosphamide, and paclitaxel. In this study, you will get either atezolizumab plus chemotherapy, trastuzumab, and pertuzumab or placebo plus chemotherapy, trastuzumab, and pertuzumab.
Clinical Study Identifier: s18-01015
ClinicalTrials.gov Identifier: NCTs18-01015
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
